Cartesian Therapeutics Inc. (RNAC) — Capital Reinvestment Ratio
Cartesian Therapeutics Inc. (RNAC) has a Capital Reinvestment Ratio of 0.45x as of September 2024, meaning it reinvests 0% of its operating cash flow ($13.69 Million) in capital expenditures ($6.20 Million). Check RNAC tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Cartesian Therapeutics Inc. Capital Reinvestment Ratio (2020–2020)
This chart tracks Cartesian Therapeutics Inc.'s Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see RNAC cash generation efficiency.
Annual Capital Reinvestment Ratio for Cartesian Therapeutics Inc. (2020–2020)
Year-by-year Capital Reinvestment Ratio for Cartesian Therapeutics Inc. from 2020 to 2020. See how much free cash does Cartesian Therapeutics Inc. generate to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 0.02x | $34.88 Million | $815.00K | — |